CN Patent

CN107405403A — 用于治疗纤维化的塞尼克韦罗

Assigned to Tobira Therapeutics Inc · Expires 2017-11-28 · 8y expired

What this patent protects

本公开包括赛尼克韦罗或其盐或溶剂合物和含有它的药物组合物在治疗炎症和结缔组织疾病和病症诸如纤维化、腹膜炎和肝损伤中的用途。

USPTO Abstract

本公开包括赛尼克韦罗或其盐或溶剂合物和含有它的药物组合物在治疗炎症和结缔组织疾病和病症诸如纤维化、腹膜炎和肝损伤中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN107405403A
Jurisdiction
CN
Classification
—
Expires
2017-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Tobira Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.